• AiCuris GmbH, of Wuppertal, Germany, said it achieved more than 50 percent patient enrollment in the second efficacy trial of herpes simplex virus (HSV) drug pritelivir (formerly AIC316). The study is comparing the potency of pritelivir to valacyclovir in reducing genital HSV shedding.